Kymera Therapeutics (KYMR) Change in Account Payables (2019 - 2026)
Kymera Therapeutics' (KYMR) quarterly Change in Account Payables came in at $8.8 million in Q1 2026, up 125.27% year-on-year from $3.9 million in Q1 2025, and up 691.82% on a QoQ basis from -$1.5 million in Q4 2025.
Kymera Therapeutics (KYMR) Change in Account Payables (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of Change in Account Payables data on file, last reported at $8.8 million in Q1 2026.
- On a quarterly basis, Change in Account Payables rose 125.27% year-over-year to $8.8 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 17.03% decrease from a year earlier, with the FY2025 full-year figure at -$2.0 million, down 543.0% from the prior year.
- Change in Account Payables for Q1 2026 stood at $8.8 million, up from -$1.5 million in the prior quarter.
- Over the last five years, Change in Account Payables for KYMR reached as high as $8.8 million in Q1 2026 and fell as low as -$4.1 million in Q2 2025.
- Historically, Change in Account Payables has averaged $519647.1 across 5 years, with a median of $31000.0 in 2024.
- On a YoY basis, Change in Account Payables climbed as much as 5122.67% in 2025 and fell as far as 13432.26% in 2025.
- Year by year, Change in Account Payables stood at -$2.1 million in 2022, then jumped by 174.03% to $1.5 million in 2023, then sank by 132.98% to -$505000.0 in 2024, then slumped by 195.25% to -$1.5 million in 2025, then surged by 691.82% to $8.8 million in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $8.8 million in Q1 2026, -$1.5 million in Q4 2025, and -$267000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 16.86 Mn |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.12 Bn | - | 8.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.82 Mn |
| Mar 31, 2026 | 8.82 Mn |
| Dec 31, 2025 | -1.49 Mn |
| Dec 31, 2025 | -1.49 Mn |
| Sep 30, 2025 | -267,000.00 |
| Sep 30, 2025 | -267,000.00 |
| Jun 30, 2025 | -4.13 Mn |
| Jun 30, 2025 | -4.13 Mn |
| Mar 31, 2025 | 3.92 Mn |
| Mar 31, 2025 | 3.92 Mn |
| Dec 31, 2024 | -505,000.00 |
| Dec 31, 2024 | -505,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | 1.53 Mn |
| Dec 31, 2023 | 1.53 Mn |